[Use of bone scintigraphy in the evaluation of bone involvement by prostatic cancer treated with a LHRH-antiandrogen combination].
D000726:Androgen Antagonists / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D007987:Gonadotropin-Releasing Hormone / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D011877:Radionuclide Imaging; D013669:Technetium Tc 99m Medronate
D000726:Androgen Antagonists; D007987:Gonadotropin-Releasing Hormone; D013669:Technetium Tc 99m Medronate
L'utilité de la scintigraphie osseuse dans l'évaluation de l'atteinte squelettique du cancer de la prostate traité à l'aide d'une association LHRH-antiandrogènes.